| BAYER |
BAYER |
90%
|
On February 16, 2024, AgPlenus entered into a licensing and collaboration agreement with Bayer for the development of a new sustainable weed control solution. |
| BAYER-AG |
BAYER-AG |
85%
|
. As of the December 31, 2025, the Company has not received any additional seed orders from ENI. c. On February 16, 2024, AgPlenus Ltd. entered into a Licensing and Collaboration Agreement (the ”Agre… |
| CORTEVA |
CORTEVA |
80%
|
In addition, Lavie Bio Ltd. was also eligible for additional future milestone payments and royalties from Corteva's sales of the products. |
| STRAUSS-GROUP |
STRAUSS-GROUP |
80%
|
Finally is an AI-driven company specializing in molecular farming for the food sector, committed to providing sustainable alternative sources to animal-based proteins using our GeneRator AI technolog… |
| SYSTASY-BIOSCIENCE-GMBH |
SYSTASY-BIOSCIENCE-GMBH |
80%
|
Collaboration with Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerat… |
| UNRAVEL-BIOSCIENCES-INC |
UNRAVEL-BIOSCIENCES-INC |
80%
|
Collaboration with Unravel Biosciences, Inc., a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine™ platform. |
| ICL |
ICL Group Ltd |
72%
|
has an exchange rate risk as it incurs operating costs in Israel, consisting principally of salaries and related personnel expenses, lease and facility expenses which are denominated in NIS, which di… |
| ICL |
ICL Group Ltd |
72%
|
Reciprocal relationship from ICL graph: Reciprocal relationship from EVGN graph: has an exchange rate risk as it incurs operating costs in Israel, consisting principally of salaries and related perso… |
| AGPLENUS-LTD |
AGPLENUS-LTD |
62%
|
o certain conditions set forth therein. Following the execution of the agreement with Lishan Biotech and the completion of phase-I of the clinical trial for BMC 128, no further activity is expected f… |
| AGRO-LEADS-LTD |
AGRO-LEADS-LTD |
62%
|
ordinary shares on a post-split basis. Odd lots may be more difficult to sell, or require greater transaction costs per share to sell, than shares in “round lots” of even multiples of 100 shares. 32 … |
| CASTERRA-AG-LTD |
CASTERRA-AG-LTD |
62%
|
o certain conditions set forth therein. Following the execution of the agreement with Lishan Biotech and the completion of phase-I of the clinical trial for BMC 128, no further activity is expected f… |
| DEAD-SEA-WORKS-LTD |
DEAD-SEA-WORKS-LTD |
62%
|
NOTE 22: - BALANCES AND TRANSACTIONS WITH OFFICERS AND CERTAIN SHAREHOLDERS (Cont.) e. Transactions with related parties: For the year ended December 31, 2024: Officers Certain shareholders Revenues … |
| EVOGENE-INC-LAVIE-BIO-INC-LAVIE-BIO-TECH-INC |
EVOGENE-INC-LAVIE-BIO-INC-LAVIE-BIO-TECH-INC |
62%
|
311 323 287 Total $ 3,853 $ 5,577 $ 2,982 (*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations. 50 Geographica… |
| EVOGENE-INDUSTRIAL-APPLICATIONS-CASTERRA-AG-LTD |
EVOGENE-INDUSTRIAL-APPLICATIONS-CASTERRA-AG-LTD |
62%
|
o certain conditions set forth therein. Following the execution of the agreement with Lishan Biotech and the completion of phase-I of the clinical trial for BMC 128, no further activity is expected f… |
| FINALLY-FOODS-LTD |
FINALLY-FOODS-LTD |
62%
|
e novel molecules to confirm their biological activity. Subsidiaries Since 2015 and until the beginning of 2025, Evogene has utilized its technology to develop various product types through dedicated… |
| HUMAN-HEALTH-BIOMICA-LTD |
HUMAN-HEALTH-BIOMICA-LTD |
62%
|
(including each of the businesses of our respective subsidiaries) and that of our collaborators’ are subject to various government regulations and, if we or our collaborators are unable to comply wit… |
| LAVIE-BIO-LTD |
LAVIE-BIO-LTD |
62%
|
o certain conditions set forth therein. Following the execution of the agreement with Lishan Biotech and the completion of phase-I of the clinical trial for BMC 128, no further activity is expected f… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
ordinary shares on a post-split basis. Odd lots may be more difficult to sell, or require greater transaction costs per share to sell, than shares in “round lots” of even multiples of 100 shares. 32 … |
| SHANGHAI-LISHAN-BIOPHARMACEUTICALS-CO |
SHANGHAI-LISHAN-BIOPHARMACEUTICALS-CO |
62%
|
e novel molecules to confirm their biological activity. Subsidiaries Since 2015 and until the beginning of 2025, Evogene has utilized its technology to develop various product types through dedicated… |
| SHANGHAI-LISHAN-BIOPHARMACEUTICALS-CO-LTD |
SHANGHAI-LISHAN-BIOPHARMACEUTICALS-CO-LTD |
62%
|
(including each of the businesses of our respective subsidiaries) and that of our collaborators’ are subject to various government regulations and, if we or our collaborators are unable to comply wit… |
| SUBSIDIARY-JURISDICTION-OWNERSHIP-INTEREST-AGPLE |
SUBSIDIARY-JURISDICTION-OWNERSHIP-INTEREST-AGPLE |
62%
|
o certain conditions set forth therein. Following the execution of the agreement with Lishan Biotech and the completion of phase-I of the clinical trial for BMC 128, no further activity is expected f… |
